Is the Renal Dosimetry for [90Y-DOTA0, Tyr3]Octreotide Accurate Enough to Predict Thresholds for Individual Patients?-Reference-Cited by-同舟云学术

Is the Renal Dosimetry for [90Y-DOTA0, Tyr3]Octreotide Accurate Enough to Predict Thresholds for Individual Patients?

Published:2003-08 Issue:4 Volume:18 Page:619-625
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Konijnenberg Mark W.¹

Affiliation:

1. Mallinckrodt, Tyco Healthcare, Petten, The Netherlands

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/108497803322287718

Reference27 articles.

1. Appendix B. Uncertainty in radiotherapy

2. Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma

3. The Limit of Renal Tolerance to X rays

4. Tolerance of normal tissue to therapeutic irradiation

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Generalized methods for predicting biological response to mixed radiation types and calculating equieffective doses (EQDX);Medical Physics;2023-08-21

2. Extensive 177Lu-PSMA Radioligand Therapy Can Lead to Radiation Nephropathy with a Renal Thrombotic Microangiopathy–like Picture;European Urology;2023-05

3. Aplicación de la metodología de matrices de riesgo para un centro de medicina nuclear de alta complejidad basado en el seguimiento y análisis de incidentes radiológicos y desviaciones;Revista Investigaciones y Aplicaciones Nucleares;2022-06-21

4. Dosimetry for Radiopharmaceutical Therapy: Current Practices and Commercial Resources;Journal of Nuclear Medicine;2021-12

5. ICRU REPORT 96, Dosimetry-Guided Radiopharmaceutical Therapy;Journal of the ICRU;2021-12